A Clinical Study On The Treatment Of Patients With Liver Failure By Double Plasma Molecule Adsorbent System

Aim:Comparing with the therapy of plasma bilirubin absorption (PBA),to evaluate the efficacy and safety of double plasma molecule adsorbent system (DPMAS) in the treatment of patients with liver failure.Method:From1st May2013to31st January2014, we evaluated29patients with liver failure receiving DPMAS therapy as the observational group, and14patients receiving PBA therapy as the control-group, all patients were on the basis of standard medical treatment. In the observational group patients received38rounds DPMAS, and in the control group patients received21rounds PBA. In order to determine therapeutic efficacy,we compared the evolution of liver function,renal function,prothrombin time,and reduction rates of some parameters after treatment between the two groups. All side effects were registered and analyzed severity throughout the study period.Results:Clinical symptoms and signs of most patients improved after treatment. The levels of some laboratory parameters were significantly lower than those before the therapy. Prothrombin time decreased significantly24-hours after the therapy compared with that of before therapy in the observational group.No statistically significant differences were observed in creatinine(Cr), urea nitrogen(BUN) and sodium(Na+),potassium(K+). The main side effects were skin rash and itching,and no other severe adverse events restricted treatment were observed.Conclusion:The DPMAS as a non-bioartificial liver support system was a safe procedure that provided temporary support for patients with liver failure,and was more helpful to improve patients’ liver function than PBA.